Association Between Circulating Cystatin C and Hyperuricemia: a Cross-Sectional Study
Guo Yanjun,Huang Hangkai,Chen Yishu,Shen Chao,Xu Chengfu
DOI: https://doi.org/10.1007/s10067-022-06139-6
2022-01-01
Clinical Rheumatology
Abstract:Circulating cystatin C has reportedly been related to cardiovascular disease, diabetes, and metabolic syndrome, apart from its traditional role in estimating the glomerular filtration rate. However, whether circulating cystatin C is related to hyperuricemia remains unclear. We included 2406 men and 1273 women who attended their annual health checkups in this study. Anthropometric and biochemical parameters were measured. Hyperuricemia was diagnosed as fasting serum uric acid > 420 µmol/L in men and women. A total of 695 (18.9%) participants were diagnosed with hyperuricemia. Hyperuricemic patients had significantly higher serum cystatin C levels than healthy controls (0.91 (0.83–1.02) versus 0.82 (0.72–0.92) mg/L, P < 0.001). Serum cystatin C levels were positively related to the prevalence of hyperuricemia, which was 5.18%, 14.76%, 22.66%, and 31.24% in participants with serum cystatin C levels in the first, second, third, and fourth quartiles, respectively (P < 0.001 for trend). In stepwise multivariate logistic regression analysis, participants with serum cystatin C in the fourth quartile had a more than twofold increased risk of hyperuricemia (OR 2.262, 95% CI 1.495–3.422; P < 0.001) compared with those with serum cystatin C in the first quartile. In subgroup analyses, the fourth quartile of cystatin C was related to increased risks of hyperuricemia in both non-obese and obese participants (OR 4.405, 95% CI 1.472–13.184, P = 0.008; OR 1.891, 95% CI 1.228–2.911, P = 0.004, respectively), in non-metabolic syndrome participants (OR 3.043, 95% CI 1.692–5.473; P < 0.001) but not in metabolic syndrome participants (OR 1.689, 95% CI 0.937–3.045; P = 0.081), and in non-non-alcoholic fatty liver disease (non-NAFLD) (OR 2.128, 95% CI 1.424–3.180; P < 0.001, respectively) and young and middle-aged participants (OR 2.235, 95% CI 1.492–3.348, P < 0.001) but not in NAFLD and elderly participants. This study revealed a positive association of circulating cystatin C with hyperuricemia.